Binuclear organometallic nickel complexes of the type [(μ‐NN){Ni(Mes)Br}2] {NN = α‐diimine chelate ligand of the type 2,5‐bis[1‐(aryl)iminoethyl]pyrazine; Mes = mesityl = 2,4,6‐trimethylphenyl} have been prepared and characterised electrochemically and spectroscopically in detail. A combination of NMR spectroscopy and quantum chemical calculations allowed the assignment of stereoisomers and their relative stability. The long‐wavelength absorptions (600–1000 nm) assignable to charge‐transfer transitions reveal a marked electronic coupling of the two metal centres over the ligand bridge via their low‐lying π* orbitals. The reversible reductive electrochemistry yields stable radical anionic complexes with mainly ligand‐centred spin density as shown by electron paramagnetic resonance (EPR) spectroscopy and UV/Vis spectroelectrochemistry of the free ligands and their nickel complexes in combination with DFT calculations. Preliminary investigations of the complexes as catalysts in Negishi cross‐coupling reactions gave promising results.
The mono-and binuclear organometallic Ni II complexes [(µ-bpym){Ni(Mes)Br} n ] (bpym = 2,2Ј-bipyrimidine; n = 1 or 2; Mes = mesityl = 2,4,6-trimethylphenyl) were prepared and characterised electrochemically and spectroscopically (NMR, UV/Vis/NIR) in detail. The long-wavelength absorptions for the binuclear complex reveal a marked electronic coupling of the two metal centres over the ligand bridge via their lowlying π*-orbitals. While the mononuclear complex undergoes rapid dissociation of the bromido ligand after one-electron reduction the binuclear derivative exhibits reversible reductive electrochemistry and both of them yield stable radi-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.